Cambridge Healthtech Institute’s 9th Annual
Precision Medicine
Clinical Implementation of Personalized Medicine, Liquid Biopsy, Biomarkers, and Companion Diagnostics
May 4-5, 2026
The Precision Medicine program of the 33rd Annual Tri-Con will bring together big pharma and healthcare leaders, investors, executives, entrepreneurs, and innovators to explore advances in precision oncology and the strategies Big Pharma is using to drive precision medicine forward. Experts will highlight innovations in liquid biopsy, biomarker and companion diagnostics development, as well as applications of precision approaches in neurology, obesity, aging, and women’s health. Innovation in genomics and multi-omic analysis, artificial intelligence, liquid biopsy, and other emerging technologies driving precision medicine will be discussed.
Coverage will include, but is not limited to:
- Personalized medicine at Big Pharma
- Liquid biopsy, biomarkers, and companion diagnostics
- Clinical implementation of genomic medicine
- Advances in precision oncology
- Precision medicine in neurology, obesity, aging, and women’s health
- Emerging technologies in genomics and multi-omic analysis
The deadline for priority consideration is November 21, 2025.
All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.
Opportunities for Participation: